2% homology with canine VEGF) mixed with a liposome–DNA complex. Immunization produced a 30% anti-tumor response rate, but without an increase in anti-canine VEGF antibody titers. No important side effects regarding blood biochemistry or impairment in wound healing were reported. We have now tested the effects of CIGB-247 vaccination in rats, rabbits and non-human primates to determine whether: (a) immunization produced an anti-VEGF IgG response, (b) immunity is tightly regulated and B-cell memory could be induced, and (c) vaccination produced detectable clinical, biochemical and histological side effects, www.selleckchem.com/products/birinapant-tl32711.html including the ability

to recover from skin deep wounds. Our results showed that CIGB-247 was able to Ponatinib research buy induce an IgG immune response specific for VEGF in the three studied species with discrete IgG antibody titers, similarly to our mouse experiments [11]. The latter could be explained by the close homology of the antigen and the self-growth factor (88.7% for rats, 94% for rabbits, and 99% for monkeys), the nature of the adjuvant, or a combination of these and other factors. In rats, as in mice, the IgG response against mouse VEGF (99% homology to

the rat molecule) suggests a breakage of B cell tolerance to the self-growth factor. The addition of montanide to CIGB-247 led to the highest titers in rats and rabbits. Sera from both species impaired the binding of KDR-Fc to human VEGF. Weekly vaccination schemes were better (rats) or similar (rabbits) inhibiting

the binding in the test, a clear indication that higher titers do not necessarily correlate with the biological effect of vaccination. Our experiments in non-human primates showed that vaccination breaks B-cell tolerance to the self-growth factor and elicits a specific and dose dependent anti-VEGF IgG response. The weekly scheme in monkeys showed a trend to higher titer values and an increased ability of the sera to block the interaction of soluble KDR-Fc with human VEGF. Purification CYTH4 of the IgG from monkey serum increased the resulting specific blocking activity, indicating that antibodies are responsible of the observed effect. The antibody titer kinetics in monkeys was demonstrative of a well-regulated humoral response. In the weekly scheme, the significant increase in antibody titers after the boosters is a clear evidence of B-cell memory, and provides an early indication that maintenance vaccinations after an induction phase should be foreseen for the clinical testing of CIGB-247, as has been shown by others [31]. Specific cytolysis of autologous “VEGF-charged” PBMC cells was shown in non-human primates, with the highest values for two animals belonging to the weekly vaccination group. The individual variation found – including negative individuals – could be indicative of the differences that are probably to be found in open populations submitted to this type of vaccination, or may reflect technical limitations of the used assay.